A cytokine receptor–targeting chimera toolbox for expanding extracellular targeted protein degradation

K Kaan Kumru (Department of Pharmaceutical Chemistry) Z Zi Yao (Department of Pharmaceutical Chemistry) B Brandon B. Holmes (Department of Neurology, University of California San Francisco) F Fangzhu Zhao (Department of Pharmaceutical Chemistry) Y Yun Zhang E Emilio Ferrara (Department of Bioengineering and Therapeutic Sciences, University of California San Francisco) T Trenton M. Peters-Clarke (Department of Pharmaceutical Chemistry) K Kevin K. Leung (Department of Pharmaceutical Chemistry) J James A. Wells

Abstract

Extracellular targeted protein degradation (eTPD) is an important new modality for manipulating the extracellular proteome. However, most eTPD receptors are expressed broadly or are restricted to the liver, limiting specific degradation in other tissues. Cytokine receptor–targeting chimeras (kineTACs) are genetically encoded bispecifics for eTPD that fuse a natural ligand like CXCL12 to an antibody, directing soluble or membrane proteins for lysosomal degradation using the widely expressed chemokine receptor CXCR7 (K. Pance et al. , Nat. Biotechnol. 41 , 273–281 (2023)]. Here, we dramatically expand the kineTAC toolbox by constructing 81 different kineTACs based on an unbiased list of cytokines, chemokines, and growth factors. Remarkably, 55 of these expressed at suitable levels for analysis without any optimization. Many of these kineTACs bind receptors that have unique cell-type expression profiles, allowing for eTPD in specific cells and tissues, and some were more potent than the original CXCL12-based kineTAC against specific targets. We further show the internalizing capability of a kineTAC can enhance the performance of antibody drug conjugates. We believe these simple, genetically encoded tools will be useful for expanding the applications for optimized or cell type–selective eTPD.

Article Details

Volume / Issue Vol. 123, Issue 4
Published January 27, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (9)

K

Kaan Kumru

Department of Pharmaceutical Chemistry

Z

Zi Yao

Department of Pharmaceutical Chemistry

B

Brandon B. Holmes

Department of Neurology, University of California San Francisco

F

Fangzhu Zhao

Department of Pharmaceutical Chemistry

Y

Yun Zhang

E

Emilio Ferrara

Department of Bioengineering and Therapeutic Sciences, University of California San Francisco

T

Trenton M. Peters-Clarke

Department of Pharmaceutical Chemistry

K

Kevin K. Leung

Department of Pharmaceutical Chemistry

J

James A. Wells